CDC vaccine committee votes unanimously to recommend Sanofi and AstraZeneca’s RSV immunization for babies

The CDC’s vac­cine ad­vi­so­ry com­mit­tee unan­i­mous­ly rec­om­mend­ed Sanofi’s RSV shot for ba­bies on Thurs­day. New­borns and in­fants un­der 8 months of age should re­ceive the Bey­for­tus (nir­se­vimab) mon­o­clon­al an­ti­body in ad­vance of the RSV sea­son, the Ad­vi­so­ry Com­mit­tee on Im­mu­niza­tion Prac­tices (ACIP) an­nounced af­ter a 10-0 vote.

The com­mit­tee al­so rec­om­mend­ed Bey­for­tus im­mu­niza­tions for chil­dren aged 8 to 19 months who are at high­er risk for RSV and go­ing in­to a sec­ond sea­son, by the same 10-0 vote. The RSV sea­son typ­i­cal­ly be­gins in No­vem­ber and runs for five months through March.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters